Methoxsalen (8-methoxypsoralen) is an effective and selective mechanism-bas
ed inhibitor of human hepatic cytochrome P-450 (CYP)2A6 in vitro, and may h
ave utility as a clinical probe for CYP2A6-catalyzed xenobiotic metabolism
in humans in vivo. This investigation explored single-dose oral methoxsalen
effects on human CYP2A6 activity in vivo, assessed by coumarin 7-hydroxyla
tion. Eleven volunteers received 50 mg of oral coumarin on two occasions in
a randomized crossover, 90 min after oral methoxsalen or nothing (controls
). Plasma and urine 7-hydroxycoumarin and plasma methoxsalen concentrations
were determined by HPLC. Methoxsalen pretreatment diminished area under th
e curve of plasma 7-hydroxycoumarin versus time by 24% (2.40 +/- 0.48 versu
s 3.20 +/- 0.55 mu g.h.ml(-1); P < .001), and also decreased plasma 7-hydro
xycoumarin C-max (0.80 +/- 0.26 versus 1.4 +/- 0.5 mu g/ml; P < .05); howev
er, 7-hydroxycoumarin concentrations were only diminished 0.75 to 2 h after
coumarin administration, but not thereafter. Methoxsalen diminished urine
7-hydroxycoumarin excretion in 0- to 1- and 1- to 2-h samples, but not ther
eafter, and total excretion was unchanged. Considerable individual variabil
ity in methoxsalen plasma concentrations was observed. There were significa
nt correlations between the decrease in plasma 7-hydroxycoumarin Cmax and p
lasma methoxsalen Cmax, but not between the decrease in plasma 7-hydroxycou
marin area under the curve and methoxsalen disposition. These results show
that single-dose oral methoxsalen, in conventional doses, was a moderately
effective inhibitor of human CYP2A6 activity in vivo, however, the duration
of inhibition was limited. Interindividual variability in the extent of CY
P2A6 inhibition appeared attributable to variability in the absorption and
first-pass clearance of methoxsalen. Alternative doses, timing, and/or rout
es of methoxsalen administration are required for greater, longer, and more
reproducible CYP2A6 inhibition than that provided by single-dose methoxsal
en.